CA2854631C - Indolealkylamino-withasteroid conjugates and method of use - Google Patents

Indolealkylamino-withasteroid conjugates and method of use Download PDF

Info

Publication number
CA2854631C
CA2854631C CA2854631A CA2854631A CA2854631C CA 2854631 C CA2854631 C CA 2854631C CA 2854631 A CA2854631 A CA 2854631A CA 2854631 A CA2854631 A CA 2854631A CA 2854631 C CA2854631 C CA 2854631C
Authority
CA
Canada
Prior art keywords
compound
withaferin
formula
hydrogen
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2854631A
Other languages
English (en)
French (fr)
Other versions
CA2854631A1 (en
Inventor
Muruganandam VEERARAGAVAN
Sanyasi R. Kalidindi
Shibnath Ghosal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natreon Inc
Original Assignee
Natreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natreon Inc filed Critical Natreon Inc
Publication of CA2854631A1 publication Critical patent/CA2854631A1/en
Application granted granted Critical
Publication of CA2854631C publication Critical patent/CA2854631C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2854631A 2011-11-07 2012-11-06 Indolealkylamino-withasteroid conjugates and method of use Active CA2854631C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556603P 2011-11-07 2011-11-07
US61/556,603 2011-11-07
US13/669,207 US9084800B2 (en) 2011-11-07 2012-11-05 Indolealkylamino-withasteroid conjugates and method of use
US13/669,207 2012-11-05
PCT/US2012/063727 WO2013070619A1 (en) 2011-11-07 2012-11-06 Indolealkylamino-withasteroid conjugates and method of use

Publications (2)

Publication Number Publication Date
CA2854631A1 CA2854631A1 (en) 2013-05-16
CA2854631C true CA2854631C (en) 2018-12-11

Family

ID=48223848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2854631A Active CA2854631C (en) 2011-11-07 2012-11-06 Indolealkylamino-withasteroid conjugates and method of use

Country Status (7)

Country Link
US (2) US9084800B2 (https=)
EP (1) EP2776462B1 (https=)
JP (1) JP6144688B2 (https=)
CN (1) CN103917558B (https=)
BR (1) BR112014010868B1 (https=)
CA (1) CA2854631C (https=)
WO (1) WO2013070619A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503990A (zh) * 2015-12-29 2016-04-20 吴金凤 一种新的睡加内酯类化合物及其制备方法和医药用途
EP3585400B1 (en) * 2017-02-27 2024-11-06 University of Pittsburgh - Of the Commonwealth System of Higher Education Anti-psychotic composition and treatment methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494698A1 (fr) * 1980-11-21 1982-05-28 Roussel Uclaf Nouveaux derives steroides 3-amino substitues, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6153198A (en) * 1999-07-13 2000-11-28 Natreon Inc. Withania somnifera composition
WO2003001881A2 (en) * 2001-06-26 2003-01-09 New York State Office Of Mental Health Cell-based high-throughput screening methods
US6713092B1 (en) 2002-12-03 2004-03-30 Natreon Inc. Withania Somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
US20050266100A1 (en) * 2004-03-30 2005-12-01 Council Of Scientific And Industrial Research Rafi Marg Process isolation of withaferin-A from plant materials and products therefrom
US20070036873A1 (en) * 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CA2658959A1 (en) 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
WO2009110546A1 (ja) 2008-03-06 2009-09-11 独立行政法人産業技術総合研究所 アシュワガンダ葉水抽出物を有効成分として含む組成物及びその製造方法
US20110230551A1 (en) 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof

Also Published As

Publication number Publication date
EP2776462A4 (en) 2015-04-08
EP2776462B1 (en) 2018-01-10
US20150320771A1 (en) 2015-11-12
US20130115316A1 (en) 2013-05-09
BR112014010868B1 (pt) 2021-07-06
BR112014010868A8 (pt) 2020-04-22
WO2013070619A8 (en) 2014-05-08
WO2013070619A1 (en) 2013-05-16
CA2854631A1 (en) 2013-05-16
CN103917558A (zh) 2014-07-09
CN103917558B (zh) 2017-04-12
JP2015501787A (ja) 2015-01-19
US9084800B2 (en) 2015-07-21
US10449206B2 (en) 2019-10-22
BR112014010868A2 (pt) 2017-06-13
JP6144688B2 (ja) 2017-06-07
EP2776462A1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
Dell’Agli et al. Potent inhibition of human phosphodiesterase-5 by icariin derivatives
JP2694479B2 (ja) カプサイシン様応答のための活性の可変スペクトルを有する化合物の新規種類、それらの組成物および用途
Zhao et al. New alkamides from maca (Lepidium meyenii)
US12280030B2 (en) Method of using a chlorogenic acid composition for supporting cognitive function
Zhu et al. 4-Hydroxybenzyl alcohol derivatives and their sedative–hypnotic activities
Ajayi et al. Acetylcholinesterase inhibitor from Anthocleista vogelii leaf extracts
Ramalingam et al. Free radical scavenging and antiepileptic activity of Leucas lanata
JP2007508317A (ja) Ｘａｎｔｈｏｃｅｒａｓｓｏｒｂｉｆｏｌｉａ抽出物を含む組成物、該抽出物から単離された化合物、それらを調製する方法、およびそれらの使用
WO2013181296A2 (en) Compositions and methods for managing weight
KR100523562B1 (ko) 손바닥선인장 추출물 및 이로부터 분리된 화합물을함유하는 신경세포 보호용 조성물
Puniani et al. Ethnopharmacology of Souroubea sympetala and Souroubea gilgii (Marcgraviaceae) and identification of betulinic acid as an anxiolytic principle
US10449206B2 (en) Indolealkylamino-withasteroid conjugates and method of use
EP3639817B1 (en) Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
Jia et al. Characteristic terpenylated coumarins from Ferula ferulaeoides as potential inhibitors on overactivation of microglia
Ochieng et al. Antinociceptive and antiplasmodial activities of cassane furanoditerpenes from Caesalpinia volkensii H. root bark
CN113461702B (zh) 酰基间苯三酚低聚体其制备方法和应用
Ma'mag et al. Funtulaticamide, a phytosphingosine-type ceramide from Funtumia elastica Preuss Stapf.(Apocynaceae) trunk bark with potential antileishmanial activity
CN110882243A (zh) 萜内酯类化合物的镇静用途
JP2003171349A (ja) 新規なジテルペン類、及びこれを用いた組成物、抗炎症剤、抗癌剤
Verotta et al. Complete characterization of extracts of Onopordum illyricum L.(Asteraceae) by HPLC/PDA/ESIMS and NMR
JP4157767B2 (ja) 退行性脳神経系疾患の予防および治療効果を有するハンゲショウ抽出物
JPS6217598B2 (https=)
Onoja et al. Acetylcholinesterase inhibition and metal chelatin g potentials of fractions and compounds isolated from Cola hispida., 10
Guo et al. Anti-inflammation compounds from the seedpods of Pongamia pinnata (L.) Pierre guided by the bioactivity and UPLC-HRESIMS
KR20050029785A (ko) 신규 세라마이드 유도체, 이의 제조방법 및 이의 용도

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251008

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251218

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260120